| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5845638 | Pulmonary Pharmacology & Therapeutics | 2015 | 6 Pages |
Abstract
FF/VI, the first once-daily ICS/LABA, can provide substantial improvement in lung functions, indicating that FF/VI should be considered for the regular treatment of ACOS.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Yoshihisa Ishiura, Masaki Fujimura, Yasutaka Shiba, Noriyuki Ohkura, Johsuke Hara, Kazuo Kasahara,